Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

This study has been completed.
Sponsor:
Collaborator:
Advance Biofactures Corporation
Information provided by (Responsible Party):
Zachary Gerut, Gerut, Zachary, M.D.
ClinicalTrials.gov Identifier:
NCT01613313
First received: June 5, 2012
Last updated: February 4, 2014
Last verified: February 2014

June 5, 2012
February 4, 2014
May 2012
September 2013   (final data collection date for primary outcome measure)
Reduction in visible surface area of the lipoma [ Time Frame: Six months post injection of study drug ] [ Designated as safety issue: No ]
The primary efficacy outcome is the visible surface area of the lipoma measured as the longest dimension (length) times the longest dimension perpendicular to length (width). Visible surface area will be determined by caliper and will be analyzed as the percent change from baseline at the 6-month post injection visit.
Same as current
Complete list of historical versions of study NCT01613313 on ClinicalTrials.gov Archive Site
Relative change in volume of the lipoma [ Time Frame: 6 months post injection of study drug ] [ Designated as safety issue: No ]
A secondary outcome is the relative change in volume of the lipoma as determined by MRI. This outcome will be analyzed as the change from baseline to 6 months post injection.
Same as current
Not Provided
Not Provided
 
A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma
A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

The purpose of this research is to evaluate the safest and most effective dose of a Food and Drug Administration (FDA) approved drug (XIAFLEX) in the treatment of lipoma (fatty tumors of varying sizes that occur commonly in the adult population). The fat in the lipoma is like normal fat except that it is enclosed in a balloon-like structure which is made of collagen (fibrous tissue). Treatment of the lipoma with an injection of XIAFLEX (a protein that breaks down collagen fibers) may dissolve the collagen/fibrous strands thereby decreasing the size of the lipoma or removing it.

Lipomas are common mesenchymal, benign, fatty tumors of varying sizes that occur in the general adult population. They usually present as painful or annoying lumps that are palpable and often visible in the subcutaneous tissue. Many subcutaneous lipomas are asymptomatic and are removed for non-medical reasons. However, they may cause the subject pain or discomfort or interfere with normal activity.

Spontaneous remission of lipomas has not been reported. A lipoma, once it presents itself, remains there for the lifetime of a person who carries it and may stay small or become larger. Alternative treatments of the lipoma are surgery or liposuction. If a large excision is performed there is the problem of having a very large scar and the accompanying issues of healing a large scar, or possible formation of a hematoma followed by consolidation of the hematoma and the remnants of a mass of scar tissue. This is often painful and more problematic than the original lipoma. liposuction also has the potential for hematoma formation followed by scar mass residual.

To avoid the complications listed above, a non-invasive method of treatment, such as enzyme mediated disassociation of adipose tissue, would be desirable. The primary aim of this study is to perform a step-wise approach in dosing to evaluate the safety and efficacy of clostridium histolyticum as a non-operative treatment for lipoma.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lipoma
Drug: Collagenase Clostridium Histolyticum
This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
Other Name: XIAFLEX
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
14
October 2013
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical history lipoma at least one year and no treatment within last 90 days
  • Lipoma diagnosed as benign
  • Lipoma is a single mass with easily definable edges
  • Lipoma has an area of 2.0 to 17 cm squared
  • Women of childbearing potential must use an acceptable method of birth control

Exclusion Criteria:

  • Lipomas on the head, neck, hand or foot, or female breast
  • Women who are nursing or pregnant
  • Subjects who have participated in any investigational drug trial within 45 days of enrollment in this study
  • Subjects with known allergy to collagenase or any of the inactive ingredients in XIAFLEX
  • Subjects with diabetes or any medical condition that would make the subject unsuitable for enrollment.
  • Subjects having a history of trauma in the area of the lipoma
  • Subjects with a history of connective tissue diseases or rheumatological diseases.
  • Subjects with uncontrolled hypertension
  • Subjects currently receiving or planning to receive anticoagulant medication except for less than 150 mg aspirin daily and over-the-counter nonsteroidal anti-inflammatory drugs) within 7 days before injection of study drug
  • Subjects having the following laboratory abnormalities:
  • ALT/AST greater than 3 times the upper limit of normal
  • Creatinine greater than 2
  • Hemoglobin/hematocrit and WBC outside the normal range
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01613313
Lipoma DE/01
No
Zachary Gerut, Gerut, Zachary, M.D.
Zachary Gerut
Advance Biofactures Corporation
Principal Investigator: Zachary E Gerut, M.D. Gerut, Zachary, M.D.
Gerut, Zachary, M.D.
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP